Intelligence · Patent portfolio
Regeneron Ireland Designated Patents
Full USPTO pharma patent portfolio for Regeneron Ireland Designated — grant dates, expiration, and drug cross-links.
- Patents
- 8,292
- Expiring ≤24m
- 426
Quick answer
Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months — use filters for patent-cliff planning.
-
US 11566228
Hemangio-colony forming cells
granted -
US 11560360
Therapeutic compounds
granted -
US 11559585
Conjugates of active pharmaceutical ingredients
granted -
US 11560366
Bicyclo[1.1.1]pentane inhibitors of dual leucine zipper (DLK) kinase for the treatment of disease
granted -
US 11560561
Modular polypeptide libraries and methods of making and using same
granted -
US 11560356
Compounds and compositions for the treatment of cancer
granted -
US 11554180
Adeno-associated virus virions with variant capsid and methods of use thereof
granted -
US 11555056
Methods and materials for treating cancer
granted -
US 11555055
Peptide inhibitors of insulin-degrading enzyme
granted -
US 11555041
Bridged bicyclic inhibitors of menin-MLL and methods of use
granted -
US 11555057
Compositions and methods for inhibiting tumor cells by inhibiting the transcription factor ATF5
granted -
US 11547551
Engineered tendon graft for rotator cuff repair
granted -
US 11547663
Unit aerosol doses for anticoagulation
granted -
US 11549113
Human alzheimer's disease and traumatic brain injury associated tau variants as biomarkers and methods of use thereof
granted -
US 11549127
Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
granted -
US 11547664
Compositions and methods for treating eosinophilic disorders
granted -
US 11547674
Protein-polymer hybrid biomaterials
granted -
US 11548953
Receptor tyrosine kinase-like orphan receptor 1 (ROR1) single chain Fv antibody fragment conjugates and methods of use thereof
granted -
US 11548899
Fused 1,4-oxazepines and related analogs as BET bromodomain inhibitors
granted -
US 11548889
Emetine auristatin compounds
granted -
US 11548945
T-cell receptor (TCR)-binding antibodies and uses thereof
granted -
US 11542560
Microbiome markers and therapies for autism spectrum disorders
granted -
US 11542229
Cationic sulfonamide amino lipids and amphiphilic zwitterionic amino lipids
granted -
US 11542341
Kit for detecting coronary artery disease comprising an MAA protein adduct and reagents that bind to antibodies
granted -
US 11542486
Human kynureninase enzyme variants having improved pharmacological properties
granted -
US 11541044
K-Ras modulators
granted -
US 11541125
Noncrushable pill formulations
granted -
US 11542410
Coatings containing enzyme for stable self-cleaning of organic stains
granted -
US 11542248
Methods and compositions for inhibiting the interaction of menin with MLL proteins
granted -
US 11542302
Modulators of melanocortin receptors for the treatment of depression and anxiety
granted -
US 11542242
Substituted piperazines as selective HDAC1,2 inhibitors
granted -
US 11536727
Therapeutic antibodies against ROR-1 protein and methods for use of same
granted -
US 11533915
Methods for making and using antimicrobial peptides
granted -
US 11534397
Nanocrystal microparticles of poorly soluble drugs and methods of production and use thereof
granted -
US 11534463
Nucleic acids encoding kynurenine depleting enzymes
granted -
US 11534333
Skin-like condoms having active ingredients to enhance a male erection and a female arousal
granted -
US 11535773
Coatings containing polymer modified enzyme for stable self-cleaning of organic stains
granted -
US 11534429
Small molecule inhibitors of bacterial efflux pumps and methods of using same
granted -
US 11530398
CRISPR-Cas effector polypeptides and methods of use thereof
granted -
US 11530421
Self-inactivating endonuclease-encoding nucleic acids and methods of using the same
granted -
US 11530259
Therapies and methods to treat TLR2-mediated diseases and disorders
granted -
US 11529257
Skin-like condoms having active ingredients to enhance a male erection and a female arousal
granted -
US 11529314
Lipid-based nanoparticles for encapsulation and sustained release of therapeutic agents
granted -
US 11530240
Catheter injectable cyclic peptide pro-gelators for myocardial tissue engineering
granted -
US 11529340
Combination for treating pain
granted -
US 11530239
Methods and compositions for treating diseases and conditions associated with gonadotropin releasing hormone receptor
granted -
US 11524985
IL-37 fusion protein and methods of making and using same
granted -
US 11524948
Prodrugs of alpha-ketoglutarate, alpha-ketobutyrate, alpha-ketoisovalerate, and alpha-ketoisohexanoate, and uses thereof
granted
Frequently asked questions
How many patents does Regeneron Ireland Designated have?
8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Regeneron Ireland Designated patents expire?
426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources · Patent directory